Gillian McGovern, Associate Editor

Hypomyelination with atrophy of the basal ganglia and cerebellum is the most severe form of TUBB4A leukodystrophy that currently has no curative treatment.

The dynamic reconfigurations in individuals taking antidepressant were higher than in non-users and controls, with no significant differences between those with MDD or an anxiety disorder.

The authors found that overall survival in patients with newly diagnosed multiple myeloma was longest for those receiving first-line autologous stem cell transplantation.

The 3 bimekizumab indications include psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.

Gepotidacin was compared with the combination of ceftriaxone and azithromycin in adolescent and adult patients with uncomplicated urogenital gonorrhea.

In addition to current treatment regimens, 2 experts discuss how available options can vary between adult and pediatric patients.

The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.

The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.

In addition to highlighting the difficulties patients face when managing plaque psoriasis and atopic dermatitis, 2 experts describe how pharmacists play a crucial role in treatment.

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Currently, ocifisertib is being evaluated in a phase 1b and 2 trial to confirm the safety and tolerability profiles in patients with acute myeloid leukemia.

Teclistamab was previously approved in October 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.

The pharmacist’s role may vary across different practices and institutions.

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.

The investigators note that patients with newly diagnosed multiple melanoma who receive quadruplet treatment have unmet needs that must be further examined in future research.

The authors emphasize that further research on a diverse population that focuses on the role of duration and lifestyle choices and neuroinflammatory markers should be performed.

Iloprost had also received Priority Review and Orphan Drug Designations for this indication, and FDA approval in 2004 for the treatment of pulmonary arterial hypertension.

Progression-free survival in the ixazomib/pegylated liposomal doxorubicin/dexamethasone group was shorter than in the ixazomib/lenalidomide/dexamethasone group.

The results indicate promising rates of complete response, manageable adverse events, and dose-dependent exposure in both dose groups.

The updated indication for the respiratory syncytial virus vaccine is for adults aged 50 to 59 with underlying conditions who are at an increased risk of contracting the virus.

Despite the tool’s ability to predict efficacy of sertraline in patients with major depressive disorder, the investigators note that future research will seek to improve the algorithm.

In addition to improved progression-free survival, patients treated with this regimen also showed improved complete response or stronger and were minimal residual disease-negative.

The pharmacy director of Baptist Health South Florida details the features and successes of medication delivery services they provide.

The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.

Approximately 41% of enrolled patients responded to NX-2127, and the BTK degrader overcame resistance to nearly all BTK mutations that were identified to cause resistance.

According to the authors, the test has promise in guiding treatment but needs further refining to obtain information beyond molecular subtyping.

The study authors note that to effectively implement tools, processes, and strategies within practices, the stigma surrounding cognitive impairment must be addressed.

Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.

Daratumumab and hyaluronidase-fihj in combination with other therapies was previously approved by the FDA in May 2020 for 8 indications in multiple myeloma.